Genomic and transcriptomic approaches reveal disease-specific risk genes (e.g., TREM2 in Alzheimer’s disease, ATXN2 in ALS) and biomarkers, enabling more precise diagnosis and personalized medicine [37]. Here, ATXN2 is linked to Alzheimer disease.